Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 28 July 2023, 06:00 HKT/SGT
Share:
    

Source: Peptomyc SL
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
OMO-103 in Phase 1b clinical trial

BARCELONA, July 28, 2023 - (ACN Newswire) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".

This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Munoz at the Hospital Gregorio Maranon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

Contact Information
Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869


Topic: Press release summary
Source: Peptomyc SL

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Salary Reality Gap: 52% of Malaysian Employees See Scope for Salary Growth, foundit Survey Reveals  
Mar 11, 2025 11:37 HKT/SGT
APEL Products Shine on the World Stage:Redefining Health and Sustainability - A Roadmap to Transformative Impact  
Mar 10, 2025 21:22 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time  
Monday, March 10, 2025 7:24:00 PM
Entertainment Expo makes grand return  
Mar 10, 2025 19:08 HKT/SGT
Hong Kong products highly rated by ASEAN e-shoppers  
Mar 10, 2025 18:35 HKT/SGT
The New Economics of Power Markets in a Low-Carbon World 2025  
Mar 10, 2025 18:20 HKT/SGT
CITIC Telecom CPC Wins Outstanding Award at 2025 Hong Kong Sustainable Development Innovation and Technology Awards  
Mar 10, 2025 17:44 HKT/SGT
Big Ideas, Bold Leaders: Big CIO Show and Awards is Where Business Meets Innovation  
Mar 10, 2025 16:41 HKT/SGT
DX Leaders Philippines 2025: Accelerating IT Innovation in a $40B Digital Economy  
Mar 10, 2025 15:34 HKT/SGT
The PropertyGuru Asia Awards Malaysia in Partnership with iProperty return with 23 new categories in 2025  
Mar 10, 2025 14:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: